The geroscience paradigm holds that aging is the primary driver of most age-related diseases, and that targeting core aging biology offers a tractable path to reducing disease burden across multiple indications simultaneously. Over the past decade, the aging biotech sector has grown steadily in company count, employment, capital raised, and clinical trial activity.
That growth is now producing regulatory outcomes. Multiple therapeutics targeting core aging mechanisms have received FDA approval; additional candidates sit in regulatory review; and more than a dozen aging-focused phase 3 trials are ongoing. Many of these interventions address mechanisms with clear potential for label expansion across disparate age-related conditions, consistent with the pipeline-in-a-pill premise — the idea that one intervention can address many age-related conditions — central to the geroscience thesis.
In this webinar, Karl R. Pfleger, PhD (AgingBiotech.info) joins us for a data-driven overview of where the field stands, which mechanisms are advancing, and what approvals to expect over the next five years.
The session will outline the current approved interventions, the regulatory review pipeline, the phase 3 landscape, and the commercial and regulatory factors shaping near-term outcomes.
Discussion Topics
- Geroscience Paradigm: Evidence that targeting core aging biology addresses multiple age-related diseases in parallel, and why this framework is efficient for reducing overall disease burden.
- Approved Interventions: Review of recent FDA approvals, including transthyretin (TTR) amyloidosis therapeutics and the first FDA-approved allogeneic mesenchymal stem cell therapy.
- Regulatory Review Pipeline: Three candidates with high probability of near-term approval, spanning mitochondrial function, anti-myostatin antibodies, and Mas receptor agonism.
- Phase 3 Landscape: Ongoing phase 3 trials and the mechanisms represented, including FGF-21, mTOR/AMPK modulation, mitochondrial support, and additional stem cell programs.
- Label Expansion and Pricing Dynamics: How narrow initial indications and rare-disease pricing models interact with the broader geroscience thesis, and what drives expansion to larger patient populations.
- Five-Year Outlook: Regulatory, investment, and policy factors that will influence the pace of approvals and sector growth.
Who Should Attend
This session is intended for biotech and pharmaceutical R&D leaders, investors, clinical researchers, and drug discovery scientists interested in the regulatory status and commercial trajectory of therapeutics targeting core aging biology.
